NRx Pharmaceuticals (NRXP) Stock Soars By 82% After Reporting Evidence ZYESAMI Prevents Mortality In Patients With Covid-19: Perfect Investment.

Last Friday, NRx’s stock closed at $8.52. Nevertheless, after announcing astonishing news, it is crashing market: the stock is currently at $15.5 in pre-market, resulting in a tremendous 82% growth. The presentation identifies a statistically significant effect of ZYESAMI (aviptadil) in stopping the rise in cytokines, commonly associated with mortality in patients with COVID-19. In the recently completed phase 2b/3 trial, patients treated with placebo had a statistically important elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI had a small increase in IL-6.
Health regulators continue to prioritize therapies for COVID-19 which help to stop the impact of IL-6 cytokines in patients with COVID-19. The anti-cytokine effect of ZYESAMI™ was additionally associated with a significant decline in 60-day mortality.

The cytokine data was collected as part of the Phase 2b/3 trial of ZYESAMI compared to placebo, in critically ill patients with COVID-19 respiratory failure. The effect was noted across a wide range of patients, suffering various levels of COVID-19 severity and treated in both tertiary care and local hospitals.

Richard McEntire

Finance and Entertainment Reporter Richard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.

Want Hot Stocks?    Yes. I Love Them No thanks